BEYANG Therapeutics Co., Ltd. is an innovative biopharmaceutical company that employs its proprietary ExCEED platforms to accelerate the process of new drug discovery and development in disease areas of significant unmet medical needs. Founders and management team each has more than 20 years of experience and worked at Pfizer, Merck, Astra Zeneca, Schring Plough and Hengrui previously. They are quite experienced in drug target selection, CADD, AIDD, bioassay screening and optimization, as well as DMPK. Together they have contributed to the development of more than 10 clinical candidate molecules, of which three drugs (Sunitinib/Axitinib/Crizotinib) have been approved by FDA and NMPA.

BEYANG has established a proprietary computer-accelerated integrated drug discovery platform, ExCEED, which utilizes novel molecular generation and optimization method MMPT and in silico DMPK simulation prediction to guide the discovery and development of preclinical candidate molecules. The platform greatly improves the efficiency and shortens the time from leads to preclinical candidates. By focusing on diseases with significant unmet medical needs such as ocular diseases and cancer, we aim to build a DreamWorks^TM-like organization in drug discovery, by building our own pipeline and collaborating with partners.